Soleno Therapeutics Stock Current Asset
| SLNO Stock | USD 52.71 3.13 5.61% |
Soleno Therapeutics fundamentals help investors to digest information that contributes to Soleno Therapeutics' financial success or failures. It also enables traders to predict the movement of Soleno Stock. The fundamental analysis module provides a way to measure Soleno Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Soleno Therapeutics stock.
At this time, Soleno Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 30th of November 2024, Total Current Assets is likely to grow to about 179.9 M, while Other Current Assets are likely to drop about 895.9 K. Soleno | Current Asset |
Soleno Therapeutics Company Current Asset Analysis
Soleno Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Soleno Current Asset Historical Pattern
Today, most investors in Soleno Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Soleno Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Soleno Therapeutics current asset as a starting point in their analysis.
Soleno Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Soleno Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Soleno Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Soleno Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Soleno Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Soleno Therapeutics could also be used in its relative valuation, which is a method of valuing Soleno Therapeutics by comparing valuation metrics of similar companies.Soleno Therapeutics is currently under evaluation in current asset category among its peers.
Soleno Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Soleno Therapeutics from analyzing Soleno Therapeutics' financial statements. These drivers represent accounts that assess Soleno Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Soleno Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 100.4M | 120.9M | 32.7M | 16.6M | 15.0M | 14.2M | |
| Enterprise Value | 80.0M | 71.8M | 11.9M | 2.2M | 2.0M | 1.9M |
Soleno Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Soleno Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Soleno Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Soleno Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 2.02 B | ||||
| Shares Outstanding | 43.12 M | ||||
| Shares Owned By Insiders | 3.04 % | ||||
| Shares Owned By Institutions | 96.96 % | ||||
| Number Of Shares Shorted | 4.74 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 8.59 X | ||||
| EBITDA | (37.03 M) | ||||
| Net Income | (38.99 M) | ||||
| Cash And Equivalents | 24.07 M | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 403 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.43 X | ||||
| Book Value Per Share | 6.45 X | ||||
| Cash Flow From Operations | (24.94 M) | ||||
| Short Ratio | 8.87 X | ||||
| Earnings Per Share | (2.79) X | ||||
| Target Price | 74.25 | ||||
| Number Of Employees | 33 | ||||
| Beta | -1.44 | ||||
| Market Capitalization | 2.41 B | ||||
| Total Asset | 180.69 M | ||||
| Retained Earnings | (276.41 M) | ||||
| Working Capital | 159.85 M | ||||
| Net Asset | 180.69 M |
About Soleno Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Soleno Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Soleno Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Soleno Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Soleno Stock
| 0.73 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.72 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.64 | BHC | Bausch Health Companies | PairCorr |
Moving against Soleno Stock
| 0.71 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | HLN | Haleon plc | PairCorr |
| 0.65 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.6 | ELAN | Elanco Animal Health | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Soleno Therapeutics Piotroski F Score and Soleno Therapeutics Altman Z Score analysis. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.